TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27785747
Drug: Chronic alkali
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic alkali therapy
Study: 27785747
Drug: No chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chronic alkali therapy
Study: 12937009
Drug: Cefaclor (CFC)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CFC) 20 mg/kg
Study: 12937009
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (AMX/CA) 20 mg/kg (4:1 ratio)
Study: 10321661
Drug: Hydrocortisone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/hr, reduced to 0.08 mg/kg/hr after shock reversal)
Study: 7577590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream applied once-daily
Study: 7577590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream applied twice-daily
Study: 7577590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream applied once-daily with vehicle cream
Study: 7577590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream applied once-daily and twice-daily
Study: 28109092
Drug: Preoperative mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative mechanical bowel preparation
Study: 28109092
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative mechanical bowel preparation
Study: 19228431
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate and booster 23-valent polysaccharide vaccine
Study: 16511715
Drug: 0.5% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isotonic solution of sodium carboxymethylcellulose (CMC)
Study: 24563419
Drug: Prescription medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription medications
Study: 10731269
Drug: Intracoronary diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary diltiazem (1 mg)
Study: 10731269
Drug: Intracoronary verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary verapamil (200 mcg)
Study: 9492666
Drug: Adjuvant psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant psychological therapy
Study: 31259608
Drug: Acetazolamide 125
Normalized name: acetazolamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 125 mg twice daily, day of ascent dosing
Study: 31259608
Drug: Acetazolamide 125
Normalized name: acetazolamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 125 mg twice daily, night before dosing
Study: 24512643
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels below 1 ng/ml
Study: 19147527
Drug: Enoxaparin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.5 mg/kg once daily
Study: 19147527
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg twice daily (Control)
Study: 17592287
Drug: Intermittent Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Sequential Pneumatic Compression (ISPC) device during pneumoperitoneum (PP)
Study: 16146494
Drug: IFN-beta-1a 44
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta-1a 44 microg subcutaneous three times weekly (t.i.w.) for 12 months
Study: 16146494
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up without IFN-beta-1a
Study: 16146494
Drug: During treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: During treatment and follow-up
Study: 9784675
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment with low‐molecular‐weight heparin
Study: 9784675
Drug: In-hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital treatment with unfractionated heparin
Study: 7840824
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Study: 7840824
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Study: 7840824
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Study: 7840824
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg i.v. of murine anti EGF‐R IgG2a mab EMD 55900
Study: 3340118
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of chemohormonal therapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, doxorubicin, tamoxifen)
Study: 3340118
Drug: 36 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36 weeks of chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone)
Study: 27575584
Drug: Whole‐body cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐body cold mist shower therapy
Study: 25611597
Drug: Typical, non‐standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical, non‐standardized physiotherapy treatment (CG)
Study: 18680695
Drug: Screened for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screened for HLA‐B*5701 before starting abacavir treatment
Study: 18680695
Drug: Epicutaneous patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicutaneous patch testing for immunological confirmation
Study: 17154749
Drug: Exposure-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based treatments
Study: 10557020
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg daily for 12 weeks
Study: 10557020
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg daily and Placebo
Study: 8533749
Drug: Mass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass treatment and behavior modification campaign
Study: 8533749
Drug: Improved face-washing
Normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved face-washing plus antibiotic treatment
Study: 1882473
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser therapy (Galium‐Aluminium‐Arsenide laser, 30 mW/830 nm, Unilaser 2000 3B)
Study: 28116431
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and compound vitamin B2, taken orally for 2 courses.
Study: 20685507
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic glimepiride 2 mg)
Study: 20685507
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded glimepiride 2 mg)
Study: 18714738
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment consisting of a 7-day administration of one proton pump inhibitor and 2 out of 3 antibiotics (amoxicillin, clarithromycin, metronidazole)
Study: 18714738
Drug: Quadruple treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple treatment regimen consisting of bismuth salts, tetracycline, metronidazole, and proton pump inhibitor
Study: 18714738
Drug: New antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antibiotics (levofloxacin and rifabutin) for Hp eradication
Study: 18714738
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment assessed with urease or breath test
Study: 12870120
Drug: Long-cycle structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-cycle structured intermittent therapy (SIT; 4 weeks without HAART followed by 8 weeks with HAART)
Study: 17972364
Drug: Continuous highly
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous highly active antiretroviral therapy (HAART)
Study: 1777297
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment from general practitioner
Study: 7048668
Drug: DEC (diethylcarbamazine)
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (diethylcarbamazine) given in spaced doses (once weekly, monthly, or bi-monthly)
Study: 7048668
Drug: DEC (diethylcarbamazine)
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (diethylcarbamazine) at a total dose of 36-48 mg/kg
Study: 7048668
Drug: DEC (diethylcarbamazine)
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (diethylcarbamazine) at a total dose of 72 mg/kg
Study: 7048668
Drug: Levamisole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (3 mg/kg) prior to DEC (6 mg/kg/day for 7 days)
Study: 7048668
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with DEC (6 mg/kg/day for 7 days)
Study: 6437366
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate and imipramine combination
Study: 26546298
Drug: Hysteroscopic local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic local anesthetic intrauterine cornual block (ICOB) plus direct local anesthetic cervical block (DCB) using 1 mL 3% mepivacaine plus 1 mL 0.5% bupivacaine
Study: 26546298
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving DCB plus ICOB with 2 mL of placebo (saline)
Study: 23465084
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of lithium plus optimized treatment (OPT)
Study: 25827507
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment (OPT) alone
Study: 20626016
Drug: Child-targeted intervention
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-targeted intervention involving massage and humor therapy
Study: 17597711
Drug: GI181771X (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI181771X (selective CCK‐A agonist)
Study: 12218519
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine pretraumatic injection
Study: 12218519
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine posttraumatic injection
Study: 12218519
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) pretraumatic injection
Study: 12218519
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) posttraumatic injection
Study: 11783195
Drug: Salvia injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia injection (SI)
Study: 11783195
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and western medicine (TCM‐WM)
Study: 8684533
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment for an average period of 18 months
Study: 16316784
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment
Study: 6295861
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Ranitidine at night
Study: 6295861
Drug: Low-dose antacid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antacid when necessary
Study: 27398918
Drug: GAA 15
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAA 15 training program (15 minutes of neuromuscular training exercises, twice weekly for 8 weeks)
Study: 11509470
Drug: 256-mg ferrous
Normalized name: ferrous gluconate 256 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 256-mg ferrous sulfate daily for 4 weeks
Study: 7958150
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of fluconazole
Study: 7958150
Drug: Single intravaginal
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravaginal dose of 500 mg clotrimazole
Study: 10991886
Drug: Praziquantel (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (1,800 mg) with high-lipid diet
Study: 10991886
Drug: Praziquantel (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (1,800 mg) with high-carbohydrate diet
Study: 3898905
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide 50 micrograms per nostril b.i.d.
Study: 3898905
Drug: Oral flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flunisolide 500 micrograms b.i.d.
Study: 3898905
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal and oral) b.i.d.
Study: 31276193
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (IV fluid therapy)
Study: 25125506
Drug: Methazolamide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (40 mg b.i.d.)
Study: 23299270
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheets applied to half of the scar for 6 months
Study: 23299270
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheets
Study: 20708858
Drug: Threat condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threat condition (believing they ingested 500 mg of disulfiram)
Study: 16208302
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion sessions (10 sessions, twice a week for 5 weeks)
Study: 16208302
Drug: AcupunctureSham (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AcupunctureSham (10 sessions, twice a week for 5 weeks)
Study: 12654073
Drug: Sensory integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integrative therapy (n=15)
Study: 12654073
Drug: Vestibular stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular stimulation in addition to sensory integrative therapy (n=15)
Study: 12654073
Drug: Neurodevelopmental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental therapy (n=15)
Study: 10477025
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment room lasers
Study: 8394538
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of Aza-CsA-P, n = 41
Study: 8394538
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy of Aza-P, n = 42
Study: 27196093
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine multilevel intervention (MLI)
Study: 27196093
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine multilevel intervention (comparison group)
Study: 27802242
Drug: Safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 100 mg/day
Study: 22948897
Drug: Safinamide 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 350 mg/day
Study: 22948897
Drug: Phenelzine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine 30 mg/day
Study: 20004013
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL water (placebo) (n=285)
Study: 18203329
Drug: Control (DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (DMARD therapy)
Study: 9469328
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg
Study: 1515448
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium blocker
Study: 7654578
Drug: Amorolfine cream
Normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorolfine cream 0.5%
Study: 2689018
Drug: Bifonazole cream
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole cream 1%
Study: 788464
Drug: Long-acting amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting amitriptyline (Diffucaps) 25 mg at evening meal
Study: 788464
Drug: Ordinary amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary amitriptyline 40 mg at bedtime
Study: 28556506
Drug: Fosdagrocorat 5
Normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosdagrocorat 5 mg
Study: 23870174
Drug: Argan oil
Normalized name: ARGAN OIL
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argan oil (25 mL/day for 3 weeks)
Study: 21585288
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg p.o. (positive control)
Study: 21585288
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg/day p.o. for 14 days
Study: 21585288
Drug: Roflumilast 1000
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 1000 μg/day p.o. for 14 days
Study: 7953259
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg per rectum
Study: 7953259
Drug: Pethidine 50
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 50 mg intravenously
Study: 7953259
Drug: Pethidine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine with intravenous benzodiazepines
Study: 2441163
Drug: Caffeine alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine alone, 250 mg intravenously (i.v.)
Study: 2441163
Drug: Adenosine alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine alone, increasing dose of 0.04‐0.16 mg/kg/min
Study: 2441163
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion after caffeine
Study: 30151409
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single dose every 6 months)
Study: 30151409
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single dose every 6 months)
Study: 26242149
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine treatment (anastrozole, exemestane)
Study: 26242149
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (doxorubicin plus paclitaxel)
Study: 26242149
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with trastuzumab
Study: 23108194
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 60 days
Study: 10809397
Drug: Remineralizing solution
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remineralizing solution only (Group A)
Study: 10809397
Drug: 35% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% phosphoric acid etching for 30 s + remineralizing solution (Group B)
Study: 10809397
Drug: Remineralizing solution
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remineralizing solution + daily fluoride toothpaste slurry (1,000 ppm for 5 min) (Group C)
Study: 10809397
Drug: 35% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% phosphoric acid etching + daily fluoride treatment (Group D)
Study: 1354432
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 0.1 g
Study: 1354432
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 0.2 g
Study: 1354432
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 0.2 g with Maalox 70 (10 ml 2h and 10 ml 15 min before)
Study: 1354432
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 0.2 g with famotidine (40 mg 1h before)
Study: 6896649
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.2 mg kg‐1 in 10% dextrose solution)